Symbols / RGC
RGC Chart
About
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 12.97B |
| Enterprise Value | 13.00B | Income | -3.58M | Sales | — |
| Book/sh | 0.01 | Cash/sh | 0.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | 10 | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | 2623.00 | P/C | — |
| EV/EBITDA | -3519.70 | EV/Sales | — | Quick Ratio | 7.38 |
| Current Ratio | 7.39 | Debt/Eq | 11.20 | LT Debt/Eq | — |
| EPS (ttm) | -0.01 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-06-02 17:00 | ROA | -33.20% |
| ROE | -54.81% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 494.49M |
| Shs Float | 18.43M | Short Float | 1.21% | Short Ratio | 1.71 |
| Short Interest | — | 52W High | 83.60 | 52W Low | 0.10 |
| Beta | 2.01 | Avg Volume | 482.42K | Volume | 59.23K |
| Target Price | — | Recom | None | Prev Close | $26.29 |
| Price | $26.23 | Change | -0.23% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$26.23
Latest analyst target
3. DCF / Fair value
$-0.05
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$26.23
Low
—
High
—
Mean
—
News
RSS: Latest RGC news- This Stock Soared 9,800% in 2025. Here's 1 Key Reason Why Investors Are Piling In (Spoiler: It's Regencell Bioscience Holdings (RGC) Stock) - The Motley Fool Mon, 24 Nov 2025 08
- Regencell Bioscience Holdings (RGC) Stock Analysis: Navigating the Volatility in a $14.42 Billion Healthcare Innovator - DirectorsTalk Interviews Mon, 23 Feb 2026 20
- Regencell Bioscience (NASDAQ:RGC) Stock Price Down 6.6% - Should You Sell? - MarketBeat Fri, 20 Feb 2026 22
- Why Is RGC Stock Soaring Today? - Stocktwits hu, 08 Jan 2026 08
- Regencell Bioscience Holdings (RGC) Climbs 11% Over Last Week - Yahoo Finance Sat, 13 Sep 2025 07
- Regencell wins extension to insider lock-ups (RGC:NASDAQ) - Seeking Alpha Fri, 13 Feb 2026 08
- This $14 Billion Meme Stock Says It Is Developing a Herbal Remedy for Autism - WSJ ue, 27 Jan 2026 08
- Responsive Playbooks and the RGC Inflection - Stock Traders Daily Sat, 21 Feb 2026 14
- Regencell Bioscience (RGC) stock swings 45% then closes up 10.6% — what to watch Monday - TechStock² Sun, 11 Jan 2026 08
- Regencell Bioscience Extends Insider Stock Lock-Up to April 2027 - The Globe and Mail Sat, 14 Feb 2026 08
- Regencell Bioscience Holdings (RGC) Valuation After Insider Lock Up Extension And Rapid Share Price Momentum - Sahm Wed, 18 Feb 2026 08
- Regencell Bioscience (NASDAQ:RGC) Shares Gap Up - Still a Buy? - MarketBeat Mon, 09 Feb 2026 08
- Why Regencell Bioscience (RGC) stock is moving today: choppy rebound after Nasdaq pauses - TechStock² Fri, 09 Jan 2026 08
- Regencell Bioscience Holdings (NasdaqCM:RGC) Announces 38:1 Stock Split Effective June 2025 - Yahoo Finance Fri, 20 Jun 2025 07
- Regencell Bioscience is the top performing pharma stock YTD (RGC:NASDAQ) - Seeking Alpha Mon, 22 Dec 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -3.99M | -5.50M | -7.01M | -1.35M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -4.30M | -5.87M | -7.45M | -1.35M |
| ReconciledDepreciation | 745.59K | 769.69K | 604.40K | 26.46K |
| EBITDA | -3.99M | -5.50M | -7.01M | -1.35M |
| EBIT | -4.74M | -6.27M | -7.62M | -1.38M |
| NormalizedIncome | -4.30M | -5.87M | -7.45M | -1.35M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -4.30M | -5.87M | -7.45M | -1.35M |
| TotalExpenses | 4.74M | 6.27M | 7.62M | 1.38M |
| TotalOperatingIncomeAsReported | -4.74M | -6.27M | -7.62M | -1.38M |
| DilutedAverageShares | 494.49M | 494.49M | 486.62M | 480.40M |
| BasicAverageShares | 494.49M | 494.49M | 486.62M | 480.40M |
| DilutedEPS | -0.01 | -0.01 | -0.02 | -0.00 |
| BasicEPS | -0.01 | -0.01 | -0.02 | -0.00 |
| DilutedNIAvailtoComStockholders | -4.30M | -5.87M | -7.45M | -1.35M |
| NetIncomeCommonStockholders | -4.30M | -5.87M | -7.45M | -1.35M |
| NetIncome | -4.30M | -5.87M | -7.45M | -1.35M |
| MinorityInterests | 61.38K | 191.20K | 148.61K | 0.00 |
| NetIncomeIncludingNoncontrollingInterests | -4.36M | -6.06M | -7.59M | -1.35M |
| NetIncomeContinuousOperations | -4.36M | -6.06M | -7.59M | -1.35M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -4.36M | -6.06M | -7.59M | -1.35M |
| OtherIncomeExpense | 373.50K | 211.34K | 23.21K | 34.62K |
| OtherNonOperatingIncomeExpenses | 373.50K | 211.34K | 23.21K | 34.62K |
| OperatingIncome | -4.74M | -6.27M | -7.62M | -1.38M |
| OperatingExpense | 4.74M | 6.27M | 7.62M | 1.38M |
| ResearchAndDevelopment | 1.07M | 1.58M | 2.51M | 438.32K |
| SellingGeneralAndAdministration | 3.67M | 4.69M | 5.11M | 943.04K |
| SellingAndMarketingExpense | 125.43K | 262.66K | 25.27K | 1.58K |
| GeneralAndAdministrativeExpense | 3.55M | 4.43M | 5.08M | 941.46K |
| OtherGandA | 3.55M | 4.43M | 5.08M | 941.46K |
| SalariesAndWages | 900.00K | 1.50M | 0.00 | |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|
| OrdinarySharesNumber | 494.49M | 494.49M | 494.49M | 480.40M |
| ShareIssued | 494.49M | 494.49M | 494.49M | 480.40M |
| NetDebt | 3.62M | |||
| TotalDebt | 85.74K | 463.67K | 771.25K | 3.68M |
| TangibleBookValue | 8.22M | 12.03M | 17.07M | -4.00M |
| InvestedCapital | 8.22M | 12.03M | 17.07M | -315.67K |
| WorkingCapital | 7.92M | 11.01M | 15.87M | -4.27M |
| NetTangibleAssets | 8.22M | 12.03M | 17.07M | -4.00M |
| CapitalLeaseObligations | 85.74K | 463.67K | 771.25K | 0.00 |
| CommonStockEquity | 8.22M | 12.03M | 17.07M | -4.00M |
| TotalCapitalization | 8.22M | 12.03M | 17.07M | -4.00M |
| TotalEquityGrossMinorityInterest | 8.22M | 11.99M | 17.08M | -4.00M |
| MinorityInterest | 0.00 | -40.90K | 15.39K | 0.00 |
| StockholdersEquity | 8.22M | 12.03M | 17.07M | -4.00M |
| GainsLossesNotAffectingRetainedEarnings | -45.77K | -86.66K | 0.00 | |
| OtherEquityAdjustments | -45.77K | -86.66K | ||
| RetainedEarnings | -21.62M | -17.32M | -11.44M | -4.00M |
| AdditionalPaidInCapital | 29.88M | 29.43M | 28.51M | 256.00 |
| CapitalStock | 130.00 | 130.00 | 130.00 | 100.00 |
| CommonStock | 130.00 | 130.00 | 130.00 | 100.00 |
| TotalLiabilitiesNetMinorityInterest | 219.51K | 632.32K | 938.03K | 4.34M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 25.93K | 25.41K | 360.27K | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 25.93K | 25.41K | 360.27K | 0.00 |
| LongTermCapitalLeaseObligation | 25.93K | 25.41K | 360.27K | 0.00 |
| CurrentLiabilities | 193.58K | 606.91K | 577.76K | 4.34M |
| CurrentDebtAndCapitalLeaseObligation | 59.81K | 438.26K | 410.99K | 3.68M |
| CurrentCapitalLeaseObligation | 59.81K | 438.26K | 410.99K | 0.00 |
| CurrentDebt | 3.68M | |||
| OtherCurrentBorrowings | 3.68M | |||
| PayablesAndAccruedExpenses | 133.77K | 168.65K | 166.78K | 655.80K |
| CurrentAccruedExpenses | 125.33K | 158.08K | 151.13K | 572.99K |
| Payables | 8.44K | 10.57K | 15.65K | 82.81K |
| DuetoRelatedPartiesCurrent | 8.44K | 10.57K | 15.65K | 82.81K |
| TotalAssets | 8.44M | 12.62M | 18.02M | 340.13K |
| TotalNonCurrentAssets | 324.20K | 1.00M | 1.57M | 273.29K |
| NonCurrentPrepaidAssets | 97.68K | 108.50K | 114.30K | 19.11K |
| NonCurrentDeferredAssets | 0.00 | 172.31K | ||
| NetPPE | 226.51K | 891.91K | 1.46M | 81.86K |
| AccumulatedDepreciation | -784.16K | -476.16K | -186.12K | -35.97K |
| GrossPPE | 1.01M | 1.37M | 1.65M | 117.84K |
| Leases | 623.80K | 621.42K | 601.53K | 117.84K |
| OtherProperties | 84.78K | 451.08K | 747.43K | |
| MachineryFurnitureEquipment | 302.10K | 295.58K | 297.19K | 0.00 |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 8.11M | 11.62M | 16.44M | 66.85K |
| PrepaidAssets | 27.60K | 7.44K | ||
| Receivables | 152.78K | 56.55K | 27.60K | 7.44K |
| OtherReceivables | 152.78K | 56.55K | 27.60K | 7.44K |
| CashCashEquivalentsAndShortTermInvestments | 7.96M | 11.56M | 16.42M | 59.41K |
| OtherShortTermInvestments | 5.00M | 10.00M | 10.00M | 0.00 |
| CashAndCashEquivalents | 2.96M | 1.56M | 6.42M | 59.41K |
| CashFinancial | 2.96M | 1.56M | 6.42M | 59.41K |
| Line Item | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|
| FreeCashFlow | -4.01M | -4.99M | -6.05M | -767.31K |
| IssuanceOfDebt | 612.06K | |||
| IssuanceOfCapitalStock | 0.00 | 0.00 | 22.67M | 0.00 |
| CapitalExpenditure | -5.38K | -27.39K | -780.88K | |
| InterestPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 2.96M | 1.56M | 6.42M | 59.41K |
| BeginningCashPosition | 1.56M | 6.42M | 59.41K | 386.98K |
| EffectOfExchangeRateChanges | 53.22K | -83.14K | 0.00 | 0.00 |
| ChangesInCash | 1.34M | -4.77M | 6.36M | -327.57K |
| FinancingCashFlow | 102.28K | 134.91K | 22.41M | 439.75K |
| CashFlowFromContinuingFinancingActivities | 102.28K | 134.91K | 22.41M | 439.75K |
| NetOtherFinancingCharges | 102.28K | 134.91K | 164.00K | -172.31K |
| NetCommonStockIssuance | 0.00 | 0.00 | 22.67M | 0.00 |
| CommonStockIssuance | 0.00 | 0.00 | 22.67M | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | -431.97K | 612.06K |
| NetShortTermDebtIssuance | 0.00 | 0.00 | -431.97K | 612.06K |
| ShortTermDebtIssuance | 612.06K | |||
| InvestingCashFlow | 5.24M | 58.98K | -10.78M | 0.00 |
| CashFlowFromContinuingInvestingActivities | 5.24M | 58.98K | -10.78M | 0.00 |
| NetInvestmentPurchaseAndSale | 5.25M | 85.40K | -10.00M | 0.00 |
| SaleOfInvestment | 10.25M | 10.09M | 0.00 | 0.00 |
| PurchaseOfInvestment | -5.00M | -10.00M | -10.00M | 0.00 |
| NetPPEPurchaseAndSale | -5.38K | -26.42K | -780.88K | 0.00 |
| SaleOfPPE | 0.00 | 970.00 | 0.00 | 0.00 |
| PurchaseOfPPE | -5.38K | -27.39K | -780.88K | 0.00 |
| OperatingCashFlow | -4.00M | -4.96M | -5.27M | -767.31K |
| CashFlowFromContinuingOperatingActivities | -4.00M | -4.96M | -5.27M | -767.31K |
| ChangeInWorkingCapital | -585.37K | -508.94K | -1.02M | 552.98K |
| ChangeInOtherCurrentLiabilities | -465.07K | -487.67K | -430.42K | 0.00 |
| ChangeInPayablesAndAccruedExpense | -34.88K | 1.87K | -489.02K | 560.80K |
| ChangeInAccruedExpense | -32.75K | 6.95K | -421.86K | 477.99K |
| ChangeInPayable | -2.13K | -5.08K | -67.16K | 82.81K |
| ChangeInPrepaidAssets | -85.42K | -23.15K | -104.62K | -7.82K |
| OtherNonCashItems | -248.00K | -85.40K | -10.73K | |
| StockBasedCompensation | 449.31K | 922.62K | 2.76M | 0.00 |
| DepreciationAmortizationDepletion | 745.59K | 769.69K | 604.40K | 26.46K |
| DepreciationAndAmortization | 745.59K | 769.69K | 604.40K | 26.46K |
| Depreciation | 745.59K | 769.69K | 604.40K | 26.46K |
| OperatingGainsLosses | 1.42K | |||
| GainLossOnSaleOfPPE | 0.00 | 1.42K | 0.00 | 0.00 |
| NetIncomeFromContinuingOperations | -4.36M | -6.06M | -7.59M | -1.35M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for RGC
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|